DnB Markets - Medistim ASA (MEDIO) Medistim (Buy, TP: NOK290.00) - Another research boost

Report

DnB Markets

Geir Hiller Holom

EUR 94.52 For Business Accounts Only

Medistim (Buy, TP: NOK290.00) - Another research boost

We expect Medistim to continue its growth in 2023 as a global market leader in the transit time flow measurement (TTFM) niche. The company’s technology recently received even more support from academia following an article in the highly regarded New England Journal of Medicine, which reported significantly better results among patients with chronic limb-threatening ischemia receiving surgery compared to those receiving endovascular therapy. We believe Medistim is a solid stock to own in 2023 and reiterate our BUY and NOK290 target price.

06/01/2023 1 EN

Underlying

Medistim ASA

Medistim is engaged in the developing, producing, service, leasing and distribution of medical devices. Co. develops, manufactures and brings to market the quality assessment systems VeriQ™ and VeriQ C™ for cardiac, vascular and transplant surgery. In addition, Co. is a distributor of other medical devices through its subsidiaries: Medistim Norge AS, Medistim Danmark Aps and Medistim Deutschland GmbH. The products distributed are mainly medical devices within all types of surgery.Minus income tax paidInbound VAT receivable

See profile

NO0010159684 Oslo Bors Norway

Provider

DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

See profile

Analysts

Geir Hiller Holom

Other Reports on these Companies

DnB Markets

Medistim (Hold, TP: NOK172.00) - Q3 report

While up 7% YOY (currency-neutral sales growth 5.3%), revenues of NOK132.8m were below our forecast of NOK136m. The EBIT margin of 24% (Q3 2023: 27%) also fell shy of our forecast of 28.6%. We still see signs that the company’s ‘going direct’ efforts should eventually bear fruit, but we now believe their effect on the revenue side and on margins will take longer to materialise than we initially expected. We also note the cardiac segment is seeing slower progress than we expected, causing us concern about longer-term growth. We have downgraded to HOLD (BUY) and cut our target price to NOK172 (1...

Free Trial

October 25, 2024 October 25, 2024 1 EN

DnB Markets

Medistim (Buy, TP: NOK190.00) - Record-high quarterly sales

Revenues of NOK144.9m were a quarterly record-high, up 5.5% YOY (currency-neutral sales +4.1%) and above our NOK135m estimate. The EBIT margin (28.5%) expanded further from its low in Q4 2023 (16.4%) and, while we believe it will continue to ‘normalise’, the company’s ‘going direct’ efforts will likely prevent it from rising significantly short-term. However, we believe these efforts are moving in the right direction, validating the strategy. We have upgraded to BUY (HOLD) but we reiterate our NOK190 target price.

Free Trial

August 18, 2024 August 18, 2024 1 EN

DnB Markets

Medistim (Hold, TP: NOK190.00) - Sales in Americas weaken

Revenues grew 3.5% YOY in Q1 (currency-neutral total sales grew 2.2%), below our estimate c6%. The EBIT margin of 24% was almost back to normal and in our view shows the low margin in Q4 2023 (16.4%) should be seen as a one-off. However, we remain concerned about revenue growth, especially in the Americas, after the fifth consecutive quarter of declining currency-neutral sales. Thus, while we reiterate our HOLD, we have lowered our 2024–2026e sales by c3–8% and cut our target price to NOK190 (210).

Free Trial

April 25, 2024 April 25, 2024 1 EN

Edda Wind (Buy, TP: NOK30.00) - Well positioned

While EBITDA was broadly in line with expectations, the Q3 report gave early signs of improved operational reliability, which we believe will be key to narrowing the discount to underlying values (the stock is trading at 0.6x P/NAV). Recent contract awards (including a new 12+12-month contract announced with the results) have made the fleet fully booked until the 2025 summer season, and three of the four 2025 newbuild deliveries are now booked directly following yard delivery. We reiterate our BUY and NOK30 target price.

Free Trial

7h / 15m 7h / 15m 1 EN

Martin Huseby Karlsen

Martin Huseby Karlsen

Valuation and market update

In this note, we show updated valuation and market statistics for the Offshore Drilling sector.

Free Trial

7h / 49m 7h / 49m 1 EN

Martin Huseby Karlsen

Martin Huseby Karlsen

Petrobras FPSO delays may hit service volumes but lengthen cycle

Being the largest global consumer of deepwater oil services, Petrobras’ strategic plans tend to get investor attention. On the positive side, its latest 5-year plan sees 5% higher E&P spending than the previous one, and has a more stable phasing between the years, which is supportive for the cycle duration. However, several FPSOs are facing significant delays, which is on the downside for oil services, leading to delays for deepwater oilfield services (primarily drilling and subsea), likely resulting in lower ‘peak volumes’ and demand being spread over a longer period. The rig count is said to...

Free Trial

8h 8h 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Medistim (Buy, TP: NOK290.00) - Another research boost

Medistim (Hold, TP: NOK172.00) - Q3 report

Medistim (Buy, TP: NOK190.00) - Record-high quarterly sales

Medistim (Hold, TP: NOK190.00) - Sales in Americas weaken

Edda Wind (Buy, TP: NOK30.00) - Well positioned

Valuation and market update

Petrobras FPSO delays may hit service volumes but lengthen cycle

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe